Alzheimer’s
Oregon State researchers track copper-driven amyloid clumping in real time, testing a copper-selective chelator
Reported by AI Image generated by AI Fact checked
Oregon State University scientists report they have monitored, second by second, how copper ions promote aggregation of amyloid-beta—an Alzheimer’s-associated protein—and how different metal-binding molecules can disrupt or reverse that clumping, using a fluorescence anisotropy approach described in a study published in ACS Omega.
A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.
Experts flag shingles vaccine, sildenafil and riluzole as leading Alzheimer’s repurposing candidates
Reported by AI Fact checked
A University of Exeter-led study funded by Alzheimer’s Society has identified three already-approved medicines—the shingles vaccine Zostavax, sildenafil (Viagra) and riluzole—as top “priority” candidates to be tested in clinical trials for Alzheimer’s disease, after a structured review of 80 existing drugs by an international expert panel.